Vasorelaxant effect of the Lippia alba essential oil and its major constituent, Citral (cas 5392-40-5), on the contractility of isolated rat aorta
-
Add time:07/22/2019 Source:sciencedirect.com
The Lippia alba (Mill.) N.E. Brown (Verbenaceae) species popularly known as lemon balm has sedative, analgesic and spasmolytic properties. This study aimed to evaluate the vasorelaxant effect of the L. alba essential oil (EOLa) and its major constituent, citral, rat on aorta. Isometric muscle contraction were induced by potassium (K 60 mM) or phenylephrine (PHE, 0.1 μM) in isolated aortic rings. EOLa and citral promoted a smooth muscle relaxant action, which was potentiated by the presence of the endothelium; PHE-induced contractions (0.1 μM) in aorta with endothelium, had EC50 values of 352.73 ± 19.39 μg/mL and 99.34 ± 7.2 μg/mL for EOLa and citral, respectively. In the presence of a nitric oxide synthase inhibitor, L-NAME, the EC50 values were 654.19 ± 10.46 μg/mL and 601.66 ± 10.922 μg/mL for EOLa and citral, respectively. EOLa and citral dose-dependently relaxed contractions induced by BAY-K 8644, a calcium channel agonist, and by Phorbol 12,13-dibutyrate an activator of protein kinase C. EOLa and citral produced a vasorelaxant effect in isolated aorta which was potentiated by the presence of endothelium. In summary, EOLa and citral, probably using several mechanisms of action, relaxed aortic smooth muscle with maximal pharmacologic efficacy.
We also recommend Trading Suppliers and Manufacturers of Citral (cas 5392-40-5). Pls Click Website Link as below: cas 5392-40-5 suppliers
Prev:Anti-hyperalgesic and anti-inflammatory effects of Citral (cas 5392-40-5) with β-cyclodextrin and hydroxypropyl-β-cyclodextrin inclusion complexes in animal models
Next:Unimolecular decomposition of ethyl lactate, CH3CH(OH)COOC2H5, upon electron impact) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Anti-hyperalgesic and anti-inflammatory effects of Citral (cas 5392-40-5) with β-cyclodextrin and hydroxypropyl-β-cyclodextrin inclusion complexes in animal models07/20/2019
- Preparation and characterization of Citral (cas 5392-40-5)-loaded solid lipid nanoparticles07/21/2019
- In vitro DNA binding studies of therapeutic and prophylactic drug Citral (cas 5392-40-5)07/19/2019
- Anti-inflammatory and anti-cancer activity of Citral (cas 5392-40-5): Optimization of Citral (cas 5392-40-5)-loaded solid lipid nanoparticles (SLN) using experimental factorial design and LUMiSizer®07/18/2019
- Physiological response of Saccharomyces cerevisiae to Citral (cas 5392-40-5) combined with thermal treatment07/17/2019
- Antifungal activity and mechanism of Citral (cas 5392-40-5), limonene and eugenol against Zygosaccharomyces rouxii07/16/2019
- Effect of drying and interfacial membrane composition on the antimicrobial activity of emulsified Citral (cas 5392-40-5)07/15/2019